ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
  • Abstract Number: 413
    S100A8 & S100A9: Alarmin Mediated Inflammation in Tendinopathy
  • Abstract Number: 1872
    Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
  • Abstract Number: L06
    Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
  • Abstract Number: 1715
    Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
  • Abstract Number: 2284
    Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
  • Abstract Number: 2565
    Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
  • Abstract Number: 2892
    Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
  • Abstract Number: 791
    Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
  • Abstract Number: 1539
    Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
  • Abstract Number: 1413
    Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
  • Abstract Number: 2191
    Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
  • Abstract Number: 962
    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
  • Abstract Number: 2219
    Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
  • Abstract Number: 2535
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
  • Abstract Number: 1573
    Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
  • Abstract Number: 1572
    Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome
  • Abstract Number: 1783
    Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories
  • Abstract Number: 360
    Sarcoidosis Induced By Immune Check Point Inhibitors
  • Abstract Number: 2539
    SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
  • Abstract Number: 2707
    Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
  • Abstract Number: 1225
    Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
  • Abstract Number: 1252
    Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
  • Abstract Number: 2790
    Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
  • Abstract Number: 1847
    Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
  • Abstract Number: 465
    Seasonal Variation in Cutaneous Flares for Pediatric Lupus
  • Abstract Number: 2766
    Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
  • Abstract Number: 2168
    Seasonal Variation in Incidence of Polymyalgia Rheumatica: A Population-Based
  • Abstract Number: 2556
    Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
  • Abstract Number: 2564
    Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
  • Abstract Number: 2585
    Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
  • Abstract Number: 2562
    Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
  • Abstract Number: 2386
    Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
  • Abstract Number: 2583
    Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
  • Abstract Number: 2553
    Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program
  • Abstract Number: 2886
    Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
  • Abstract Number: 2568
    Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
  • Abstract Number: 2608
    Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
  • Abstract Number: 1189
    Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
  • Abstract Number: 936
    Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
  • Abstract Number: 2683
    Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
  • Abstract Number: 2174
    Self-Report of Fracture History Compared to Fracture Codes from an Electronic Health Record Dataset
  • Abstract Number: 1950
    Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016
  • Abstract Number: 489
    Self-Reported Depression in Patients with Rheumatoid Arthritis Is Undertreated and Associated with Poorer Clinical Status and Lower Rates of Remission in Routine Care
  • Abstract Number: 715
    Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
  • Abstract Number: 1976
    Sequencing of the MHC Region Defines HLA-DQA1 As Driven Risk for Anti-Citrullinated Protein Antibodies (ACPA)-Positive Rheumatoid Arthritis in Han Population
  • Abstract Number: 1091
    Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients
  • Abstract Number: 1637
    Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
  • Abstract Number: 1093
    Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1221
    Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
  • Abstract Number: 1070
    Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
  • Abstract Number: 2266
    Serum 1,25(OH)2 Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis
  • Abstract Number: 735
    Serum Albumin at One Year Predicts Long-Term Renal Outcome
  • Abstract Number: 1477
    Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. a Simulation Study in the United States of America
  • Abstract Number: 1680
    Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
  • Abstract Number: 172
    Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study
  • Abstract Number: 1708
    Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
  • Abstract Number: 880
    Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
  • Abstract Number: 2121
    Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
  • Abstract Number: 1784
    Serum IgG4 Test Characteristics: Immunonephelometry Versus Liquid Chromatography Tandem Mass Spectrometry
  • Abstract Number: 2066
    Serum IL-37 Is an Efficient Biomarker of Disease Activity and Treatment Response in Patients with Ankylosing Spondylitis
  • Abstract Number: 2046
    Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies
  • Abstract Number: 905
    Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Abstract Number: 877
    Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease
  • Abstract Number: 2041
    Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis
  • Abstract Number: 2880
    Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
  • Abstract Number: 1743
    Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
  • Abstract Number: 1061
    Serum Metabolomic Profiling Predicts Synovial Gene Expression in Rheumatoid Arthritis
  • Abstract Number: 1498
    Serum MMP-3 More Than 155ng/Ml at Baseline Predicts One-Year Radiographic Progression in Patients with Rheumatoid Arthritis
  • Abstract Number: 2252
    Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis
  • Abstract Number: 2230
    Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
  • Abstract Number: 2672
    Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients
  • Abstract Number: 2904
    Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
  • Abstract Number: 341
    Setting Treatment Target for Joint Surgery in Lower Limbs in Patients with Long-Standing Rheumatoid Arthritis Based on Multicenter Prospective Cohort Study; Validation and Reliability of Objective Index of Activity Speed (Timed Up and Go test) for Measuring Physical Function
  • Abstract Number: 390
    Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
  • Abstract Number: 2726
    Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors
  • Abstract Number: 1564
    Severe, Life-Threatening Phenotype of Primary Sjögren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry)
  • Abstract Number: 2243
    Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
  • Abstract Number: 1496
    Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
  • Abstract Number: 2495
    Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters
  • Abstract Number: 2325
    Sex Differences in the Association of Frailty and Bone Mineral Density in Patients with Rheumatoid Arthritis
  • Abstract Number: 2796
    Sex-Based Differences Control ABC Function in Swef-Deficient Mice
  • Abstract Number: 1170
    Sex-Specific Associations between Systemic Inflammatory Cytokines and Osteoarthritis Knee Pain
  • Abstract Number: 108
    Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
  • Abstract Number: 2365
    Sex, Language and Age of Disease Onset Impact Illness Perceptions Among RA Patients
  • Abstract Number: 385
    Sexual Dysfunction in Female Patients with Idiopathic Inflammatory Myopathies
  • Abstract Number: 1726
    Sexual Dysfunction in Systemic Sclerosis Female Patients
  • Abstract Number: 810
    Sexual Dysfunction in Women with Systemic Sclerosis
  • Abstract Number: 13
    Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies
  • Abstract Number: 1780
    Shear Wave Elastography in the Evaluation of Submandibular Gland Characteristics in IgG4-Related Disease
  • Abstract Number: 262
    Shedding Light on Fibromyalgia: Emotional Regulation Processes and Executive Functions Join Together
  • Abstract Number: 5
    Short Chain Fatty Acid Acetate Induces Regulatory B Cells in Mice and Humans, Which Can Protect Against Arthritis
  • Abstract Number: 946
    Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells
  • Abstract Number: 1733
    Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
  • Abstract Number: 2822
    Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
  • Abstract Number: 1106
    Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Peripheral Blood Mononuclear Cells of Systemic Sclerosis Patients: Correlation with Disease Specific Manifestations
  • Abstract Number: 1047
    Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway
  • Abstract Number: 2714
    Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis
  • Abstract Number: 428
    Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness
  • Abstract Number: 2593
    Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
  • Abstract Number: 606
    Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
  • Abstract Number: 1257
    Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
  • Abstract Number: 1213
    Simplified Salivary Gland Ultrasonography for Sjögren Syndrome and Sicca Symptoms: Experience from a Single Medical Center in Taiwan
  • Abstract Number: 1533
    Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
  • Abstract Number: 1067
    Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model
  • Abstract Number: 781
    Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
  • Abstract Number: 2903
    Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
  • Abstract Number: 1897
    Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway
  • Abstract Number: 928
    Single Cell RNA-Sequencing of Rheumatoid Synovial Fibroblasts Reveals a Disease-Associated Spatial Gradient Modulated By Inductive Notch Signaling
  • Abstract Number: 77
    Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis
  • Abstract Number: 110
    Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
  • Abstract Number: 1939
    Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
  • Abstract Number: 2799
    Sjogren’s Syndrome Minor Salivary Gland CD4+ T Cells Associate with Oral Disease Features and Have a T Follicular Helper-like Transcriptional Profile
  • Abstract Number: 1579
    Sjögren’s Syndrome Is Associated with Reduced Sex Hormone Exposure: A Case-Control Study
  • Abstract Number: 2809
    Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
  • Abstract Number: 1718
    Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
  • Abstract Number: 1888
    SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
  • Abstract Number: 1854
    SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
  • Abstract Number: 2676
    SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
  • Abstract Number: 2655
    SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting
  • Abstract Number: 2667
    Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
  • Abstract Number: 2643
    Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
  • Abstract Number: 1834
    Sleep Apnea and Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry
  • Abstract Number: 144
    Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA
  • Abstract Number: 1648
    Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
  • Abstract Number: 2156
    Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort
  • Abstract Number: 345
    Snap Crackle Pop: Healing the Cracks in Our Referral Process, Helping Pediatric Rheumatology Patients Get Care Sooner
  • Abstract Number: 2372
    Social Media Use for Health-Related Purposes By People with Rheumatic and Musculoskeletal Diseases – Results of a Global Survey
  • Abstract Number: 2505
    Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
  • Abstract Number: 2957
    Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis
  • Abstract Number: 274
    Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
  • Abstract Number: 716
    Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease
  • Abstract Number: 1576
    Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome
  • Abstract Number: 1577
    Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome
  • Abstract Number: 713
    Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
  • Abstract Number: 1134
    Some Is Better Than None: Minimum Physical Activity Threshold to Prevent Disability in Older Adults with Lower Extremity Joint Symptoms
  • Abstract Number: 2376
    Something for Us: Client Perspectives on Lupus Self-Management Programming Using the 5-a Behavior Change Model
  • Abstract Number: 1210
    Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
  • Abstract Number: 1641
    Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands
  • Abstract Number: 683
    Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis
  • Abstract Number: 1097
    Spatial-Time Cluster Analysis of SLE Disease Activity
  • Abstract Number: 2187
    Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
  • Abstract Number: 2045
    Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease
  • Abstract Number: 1877
    Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
  • Abstract Number: 1806
    Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
  • Abstract Number: 768
    Spinal Cord Syndromes Associated with Systemic Lupus Erythematous: Differentiating Lupus Myelitis, Neuromyelitis Optica, and Multiple Sclerosis
  • Abstract Number: 634
    Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis
  • Abstract Number: 2924
    Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort
  • Abstract Number: 1228
    Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
  • Abstract Number: 2312
    Spontaneous Vertebral Fractures after Denosumab Discontinuation
  • Abstract Number: 2901
    Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels
  • Abstract Number: 1959
    Stability of DNA Methylation Signature in Primary RA Synovial Fibroblasts Compared with Cultured Fibroblast-like Synoviocytes
  • Abstract Number: 1078
    Standardization of Synovial Biopsies Procedures across Centers: A Consensus Initiative Using a Delphi Survey
  • Abstract Number: 1162
    Standing Balance and Walking Time Among Older Adults with and without Joint Hypermobility: The Johnston County Osteoarthritis Project
  • Abstract Number: 2453
    Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
  • Abstract Number: 2126
    STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
  • Abstract Number: 408
    State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief
  • Abstract Number: 623
    Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
  • Abstract Number: 481
    Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
  • Abstract Number: 2197
    Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
  • Abstract Number: 462
    Steroid Use in Pediatric Proliferative Lupus Nephritis
  • Abstract Number: 979
    Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
  • Abstract Number: PP07
    Strengthening My Resiliency: How My Interprofessional Healthcare Team and I Improved My Management of Lupus
  • Abstract Number: 1805
    Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease
  • Abstract Number: 1120
    Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort
  • Abstract Number: 1287
    Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents
  • Abstract Number: 865
    Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study
  • Abstract Number: 677
    Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China
  • Abstract Number: 436
    Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
  • Abstract Number: 2460
    Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
  • Abstract Number: 1054
    Study of the Metabolic Effect of MSCs on Their Chondroprotective and Regenerative Properties: Modulating Their Metabolism to Improve Their Therapeutic Potential for the Treatment of Osteoarthritis
  • Abstract Number: L02
    Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
  • Abstract Number: 309
    Sub-Clinical Disease Activity in the Feet of Patients with Early Rheumatoid Arthritis: What Clinical Assessments Miss
  • Abstract Number: 1650
    Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
  • Abstract Number: 707
    Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
  • Abstract Number: 2378
    Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
  • Abstract Number: 2293
    Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
  • Abstract Number: 690
    Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
  • Abstract Number: 573
    Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
  • Abstract Number: 1770
    Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis
  • Abstract Number: 2299
    Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
  • Abstract Number: 2038
    Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
  • Abstract Number: 1385
    Subjective Well-Being Among Rheumatoid Arthritis Patients
  • Abstract Number: 1222
    Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care
  • Abstract Number: 166
    Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack
  • Abstract Number: 1212
    Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis
  • Abstract Number: 616
    Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
  • Abstract Number: PP13
    Support Groups and Patient Centred Care; Making a Difference in the Lives of People with Autoimmune and Rheumatic Conditions in Ghana
  • Abstract Number: 66
    Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators
  • Abstract Number: 1000
    Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine
  • Abstract Number: 823
    Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings
  • Abstract Number: 2609
    Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
  • Abstract Number: 1485
    Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
  • Abstract Number: 2820
    Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
  • Abstract Number: 2899
    Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
  • Abstract Number: 1659
    Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
  • Abstract Number: 1869
    Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
  • Abstract Number: PP02
    Sustained Weight Loss Managed by Multiple Medical Specialists
  • Abstract Number: 179
    Swimming Against the Stream- the Fishbowl Discussion Method As an Interactive Tool for Medical Conferences – Experiences from the 11. European Lupus Meeting
  • Abstract Number: 2533
    Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
  • Abstract Number: 322
    Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State?
  • Abstract Number: 1172
    Symptoms Compatible with Osteoarthritis and Self-Reported Osteoarthritis in the Population: Findings from the Canadian Longitudinal Study on Aging
  • Abstract Number: 1218
    Synovial Fluid Culture: Comparison of Two Culture Methods
  • Abstract Number: 2047
    Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels
  • Abstract Number: 1232
    Synovial Fluid Profile in Neutropenic Patients with Septic Arthritis
  • Abstract Number: 1053
    Synovial Inflammation Identifies Patients Clusters in Osteoarthritis
  • Abstract Number: 1506
    Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort
  • Abstract Number: 368
    Synovianalysis Using Leukocyte Esterase Reagent Strips
  • Abstract Number: 2906
    Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
  • Abstract Number: 2830
    Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features
  • Abstract Number: 2221
    Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
  • Abstract Number: 2345
    Systematic Review of Patient Decision Aids for Chronic Musculoskeletal Pain
  • Abstract Number: 1756
    Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis
  • Abstract Number: 1642
    Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
  • Abstract Number: 1371
    Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis
  • Abstract Number: 1290
    Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
  • Abstract Number: 395
    Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
  • Abstract Number: 2932
    Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
  • Abstract Number: 2359
    Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
  • Abstract Number: 1687
    Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales
  • Abstract Number: 1103
    Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations
  • Abstract Number: 1440
    Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US
  • Abstract Number: 2739
    Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology